Werewolf and Ambros to tie the knot in $150M rare disease deal
Werewolf and Ambros to tie the knot in $150M rare disease deal
Werewolf Therapeutics
HOWL $0.87 USD
Services: Conditionally activated proinflammatory immune modulators (INDUKINE programs WTX-124, WTX-330) targeting tumor microenvironment | Leadership: Dan Hicklin PhD (Founder/CEO), Cynthia Seidel-Dugan (CSO), Reid Leonard (COO) | Keywords: immuno-oncology, INDUKINE, tumor microenvironment, proinflammatory modulators
Company Info
Recent News
Werewolf transforms into Ambros via reverse merger
Werewolf transforms into Ambros via reverse merger